Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.650
+0.100 (6.45%)
At close: Oct 17, 2025, 4:00 PM EDT
1.612
-0.038 (-2.33%)
After-hours: Oct 17, 2025, 7:32 PM EDT
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
13.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SNGX News
- 4 days ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 11 days ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 18 days ago - Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 19 days ago - Soligenix Announces Closing of $7.5 Million Public Offering - PRNewsWire
- 22 days ago - Soligenix Announces Pricing of $7.5 Million Public Offering - PRNewsWire
- 25 days ago - Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor - PRNewsWire
- 6 weeks ago - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - PRNewsWire
- 6 weeks ago - Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire